SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Wiklund T) srt2:(2005-2009)"

Sökning: WFRF:(Wiklund T) > (2005-2009)

  • Resultat 1-10 av 47
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  • Wilking, N., et al. (författare)
  • Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
  • 2007
  • Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 18:4, s. 694-700
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: The purpose was to investigate adjuvant marrow-supportive high-dose chemotherapy compared with an equitoxicity-tailored comparator arm. Patients and methods: Five hundred and twenty-five women below theage of 60 years with operated high-risk primary breast cancer were randomised to nine cycles of granulocyte colony-stimulating factor supported and individually tailored FEC (5-fluorouracil, epirubicin, cyclophosphamide), (n = 251) or standard FEC followed by marrow-supported high-dose therapy with CTCb (cyclophosphamide, thiotepa, carboplatin) therapy (n = 274), followed by locoregional radiotherapy and tamoxifen for 5 years. Results: There were 104 breast cancer relapses in the tailored FEC group versus 139 in the CTCb group (double triangular method by Whitehead, P = 0.046), with a median follow-up of all included patients of 60.8 months. The event-free survival demonstrated 121 and 150 events in the tailored FEC- and CTCb group, respectively [P = 0.074, hazard ratio (HR) 0.804, 95% confidence interval (CI) 0.633-1.022]. Ten patients in the tailored FEC regimen developed acute myeloid leukaemia (AML)/myelodysplasia (MDS). One hundred deaths occurred in the tailored FEC group and 121 in the CTCb group (P = 0.287, HR 0.866, 95% CI 0.665-1.129). Conclusion: The update of this study shows an improved outcome linked to the tailored FEC treatment in relation to breast cancer relapse, but also an increased incidence of AML/MDS. © 2007 Oxford University Press.
  •  
4.
  •  
5.
  • Amundadottir, Laufey T., et al. (författare)
  • A common variant associated with prostate cancer in European and African populations
  • 2006
  • Ingår i: Nature Genetics. - DeCODE Genet, IS-101 Reykjavik, Iceland. Univ Iceland, Landspitali Hosp, Dept Pathol, IS-101 Reykjavik, Iceland. Univ Iceland, Landspitali Hosp, Dept Urol, IS-101 Reykjavik, Iceland. Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA. Orebro Univ Hosp, Dept Urol & Clin Med, Orebro, Sweden. Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden. Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA. Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA. Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA. Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. : Springer Science and Business Media LLC. - 1061-4036 .- 1546-1718. ; 38:6, s. 652-658
  • Tidskriftsartikel (refereegranskat)abstract
    • With the increasing incidence of prostate cancer, identifying common genetic variants that confer risk of the disease is important. Here we report such a variant on chromosome 8q24, a region initially identified through a study of Icelandic families. Allele -8 of the microsatellite DG8S737 was associated with prostate cancer in three case-control series of European ancestry from Iceland, Sweden and the US. The estimated odds ratio (OR) of the allele is 1.62 (P = 2.7 x 10(-11)). About 19% of affected men and 13% of the general population carry at least one copy, yielding a population attributable risk (PAR) of approximately 8%. The association was also replicated in an African American case-control group with a similar OR, in which 41% of affected individuals and 30% of the population are carriers. This leads to a greater estimated PAR (16%) that may contribute to higher incidence of prostate cancer in African American men than in men of European ancestry.
  •  
6.
  •  
7.
  • Björkblom, Carina, et al. (författare)
  • Estrogen- and androgen-sensitive bioassays based on primary cell and tissue slice cultures from three-spined stickleback (Gasterosteus aculeatus)
  • 2007
  • Ingår i: Comparative Biochemistry and Physiology - Part C. - Oxford : Elsevier. - 1532-0456 .- 1878-1659. ; 146:3, s. 431-442
  • Tidskriftsartikel (refereegranskat)abstract
    • Endocrine disrupting compounds are chemicals that may interfere with the endocrine system causing severe effects in organisms. The three-spined stickleback (Gasterosteus aculeatus L.) offers a potential for the assessment of endocrine disruption caused by a) estrogenic xenobiotics through the estrogen-dependent protein vitellogenin and b) androgenic xenobiotics through the androgen-dependent protein spiggin. The stickleback is presently the only known fish species with a quantifiable androgen and anti-androgen biomarker endpoint. In the current study, hepatocyte and kidney primary cell cultures and liver and kidney tissue slice cultures were prepared and used for detecting estrogenic or androgenic activity in vitro through the action of hormones or municipal sewage water. The results indicate that stickleback male hepatocyte cultures are suitable in detecting estrogenic activity and stickleback female kidney tissue slice cultures in detecting androgenic activity. The tested sewage water showed high estrogenic activity but no significant androgenic activity. Primary cell and tissue slice cultures isolated from the three-spined stickleback will allow simultaneously screening in vitro for potential estrogenic and androgenic activity of complex samples.
  •  
8.
  •  
9.
  • Dahlöf, Björn, 1953, et al. (författare)
  • Felodipine-metoprolol combination tablet: maintained health-related quality of life in the presence of substantial blood pressure reduction
  • 2005
  • Ingår i: Am J Hypertens. - : Oxford University Press (OUP). - 0895-7061. ; 18:10, s. 1313-9
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Most treated hypertensive patients do not achieve adequate blood pressure (BP) control. Initiating therapy with two drugs has been suggested when BP is >20/10 mm Hg above goal. To ensure patients' compliance, such treatment needs to be well tolerated and must not compromise health-related quality of life (HRQL). The primary objective of this study was to compare the effects on HRQL of initiating treatment with felodipine + metoprolol (F+M) fixed combination tablets, or enalapril (E), or placebo (P). METHODS: A total of 947 patients of both sexes with primary hypertension (diastolic BP 95 to 110 mm Hg), aged 20 to 70 years, participated in this randomized, double-blind, parallel group, 12-week, multicenter trial. Treatment was initiated with F+M 5 + 50 mg, or E 10 mg, or P. Doses were doubled after 4 or 8 weeks if diastolic BP was >90 mm Hg. The HRQL was measured at baseline and at the last visit using two validated questionnaires: the Psychological General Well-being Index (PGWB) and the Subjective Symptom Assessment Profile (SSA-P). Office BP was measured at trough, that is, 24 h after the previous dose. RESULTS: The HRQL was high at baseline and generally well maintained during the study. For example, the mean (SD) PGWB total score was 104 (16) at baseline and 105 (16) at 12 weeks in all three treatment groups. The BP reductions after F+M (18/14 mm Hg) and E (12/9 mm Hg) were significantly greater than after P (7/7 mm Hg), and the reduction after F+M was significantly greater than after E. CONCLUSIONS: The HRQL is maintained in the presence of substantial BP reduction during antihypertensive treatment with F+M fixed combination tablets.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 47
Typ av publikation
tidskriftsartikel (34)
konferensbidrag (10)
proceedings (redaktörskap) (2)
rapport (1)
Typ av innehåll
refereegranskat (39)
övrigt vetenskapligt/konstnärligt (8)
Författare/redaktör
Wiklund, F (6)
Wiklund, NP (5)
Bergh, J (4)
Wiklund, Johan (4)
Wiklund, Fredrik (4)
Gronberg, H (4)
visa fler...
Nilsson, J. (3)
Malmström, Per (3)
Erikstein, B (3)
Adami, Hans Olov (3)
Karlsson, M (3)
de Verdier, PJ (3)
Schleutker, J (3)
Xu, JF (3)
Isaacs, WB (3)
Cooney, KA (3)
Wright, M. (2)
Berglin, L (2)
SCHAID, DJ (2)
Lindecrantz, Kaj (2)
Giles, GG (2)
Johansson, Jan-Erik (2)
Wiklund, P (2)
Hopper, JL (2)
Mathiesen, T (2)
Hedelin, Maria (2)
Humphries, S. E. (2)
Whittemore, AS (2)
Thorleifsson, Gudmar (2)
Thorsteinsdottir, Un ... (2)
Stefansson, Kari (2)
Ehren, I (2)
Tammela, TLJ (2)
Thibodeau, SN (2)
McDonnell, SK (2)
Stanford, JL (2)
Maier, C (2)
Ostrander, EA (2)
Karlsson, S. (2)
Ekman, S (2)
Sharma, H S (2)
Wiklund, U. (2)
Sulem, Patrick (2)
Gudmundsson, Julius (2)
Agnarsson, Bjarni A. (2)
Sigurdsson, Asgeir (2)
Benediktsdottir, Kri ... (2)
Jakobsdottir, Margre ... (2)
Kostic, Jelena (2)
Magnusdottir, Dropla ... (2)
visa färre...
Lärosäte
Karolinska Institutet (23)
Umeå universitet (13)
Göteborgs universitet (6)
Uppsala universitet (5)
Mälardalens universitet (4)
Jönköping University (4)
visa fler...
Lunds universitet (4)
Kungliga Tekniska Högskolan (3)
Örebro universitet (3)
Luleå tekniska universitet (2)
Stockholms universitet (2)
Linköpings universitet (1)
visa färre...
Språk
Engelska (47)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (9)
Teknik (3)
Naturvetenskap (2)
Samhällsvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy